Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes

被引:7
|
作者
Hauck, Gesa [1 ]
Jonigk, Danny [1 ]
Goehring, Gudrun [2 ]
Kreipe, Hans [1 ]
Hussein, Kais [1 ]
机构
[1] Hannover Med Sch, Inst Pathol, Hannover, Germany
[2] Hannover Med Sch, Inst Cell & Mol Pathol, Hannover, Germany
关键词
Myeloproliferative neoplasm; MPN; chromosome; chromosomal defect; fibrosis; ERCC1; KLINEFELTER-SYNDROME; CYTOGENETIC ABNORMALITIES; ESSENTIAL THROMBOCYTHEMIA; BCR-ABL; JAK2; EXPRESSION; DISORDERS; REPAIR; CONSEQUENCES; MALIGNANCIES;
D O I
10.1016/j.cancergen.2013.02.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPN), non-specific chromosomal defects are detectable and essential thrombocythemia (ET) has the lowest rate of aberrations, whereas primary myelofibrosis (PMF) and post-polycythemia vera (PV) myelofibrosis have the highest rates of aberrations. The frequency of cytogenetic defects in pre-fibrotic stage PMF has not been characterized thus far and the underlying molecular defects of chromosomal instability are unknown. In this study, histopathological findings were correlated with cytogenetic data (n = 249). The expression of DNA repair factors ERCC1 and LIG4 were determined in Ph- MPN with and without cytogenetic aberrations. Pre-fibrotic PMF and ET have similarly low frequencies of karyotype anomalies. The expression of ERCC1, but not LIG4, is increased in fibrotic stage PMF but is not associated with accumulation of cytogenetic defects. In conclusion, aberrant karyotypes in Ph- MPN reflect the chromosomal instability in these diseases and, in comparison with pre-fibrotic stages, Ph- MPN with fibrosis has the highest frequency of cytogenetic aberrations.
引用
收藏
页码:116 / 123
页数:8
相关论文
共 50 条
  • [1] Impact of Comorbidities in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Ahmed, Shima A.
    Aly, Mai M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S336 - S336
  • [2] Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms
    Miguel Torregrosa, Jose
    Soler, Gloria
    Cancio, Shirley
    Ferrer-Marin, Francisca
    [J]. MEDICINA CLINICA, 2015, 145 (07): : 318 - 319
  • [3] Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Cristina, Sergio Ferreira
    Polo, Blanca
    Lacerda, Joao F.
    [J]. SEMINARS IN HEMATOLOGY, 2018, 55 (04) : 215 - 222
  • [4] Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
    Shallis, Rory M.
    Zeidan, Amer M.
    Wang, Rong
    Podoltsev, Nikolai A.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (02) : 177 - 189
  • [5] Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Vannucchi, Alessandro M.
    Masala, Giovanna
    Antonioli, Elisabetta
    Susini, Maria Chiara
    Guglielmelli, Paola
    Pieri, Lisa
    Maggi, Laura
    Caini, Saverio
    Palli, Domenico
    Bogani, Costanza
    Ponziani, Vanessa
    Pancrazzi, Alessandro
    Annunziato, Francesco
    Bosi, Alberto
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (07) : 2068 - 2073
  • [6] Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options
    Gotoh, Akihiko
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (05) : 616 - 618
  • [7] Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Zeeh, Franziska C.
    Meyer, Sara C.
    [J]. HAMOSTASEOLOGIE, 2021, 41 (03): : 197 - 205
  • [8] Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
    Holmstrom, Morten Orebo
    Hasselbalch, Hans Carl
    Andersen, Mads Hald
    [J]. CANCERS, 2020, 12 (07) : 1 - 21
  • [9] Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis
    Gowin, Krisstina
    Mesa, Ruben
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (12) : 1603 - 1611
  • [10] Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options
    Akihiko Gotoh
    [J]. International Journal of Hematology, 2022, 115 : 616 - 618